Skye Bioscience, Inc.
SKYE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $103,258 | $19,056 | $7,936 | $21,138 |
| - Cash | $68,416 | $1,256 | $1,245 | $8,983 |
| + Debt | $456 | $4,615 | $1,983 | $2,136 |
| Enterprise Value | $35,298 | $22,415 | $8,674 | $14,291 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$25,291 | -$36,620 | -$18,696 | -$7,718 |
| % Margin | – | – | – | – |
| Net Income | -$26,567 | -$37,645 | -$19,482 | -$8,522 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.73 | -5.37 | -8.77 | -5 |
| % Growth | 86.4% | 38.8% | -75.4% | – |
| Operating Cash Flow | -$25,237 | -$13,952 | -$12,744 | -$6,475 |
| Capital Expenditures | -$1,604 | -$13 | -$28 | -$91 |
| Free Cash Flow | -$26,842 | -$13,965 | -$12,772 | -$6,566 |